Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BIO
BIO logo

BIO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Bio Rad Laboratories Inc (BIO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
291.090
1 Day change
-1.65%
52 Week Range
343.120
Analysis Updated At
2026/04/10
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Bio-Rad Laboratories Inc (BIO) is not a strong buy for a beginner, long-term investor at this time. The stock shows weak financial performance, negative analyst sentiment, and lacks positive catalysts. While hedge funds are buying, the company's growth engine faces challenges, and there is no strong technical or proprietary trading signal to justify immediate entry.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 53.815, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot point of 276.48, with resistance at 285.835 and support at 267.124. Overall, the technical indicators suggest a lack of strong momentum in either direction.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
11

Positive Catalysts

  • Hedge funds are significantly increasing their positions in the stock, with a 333305.80% increase in buying over the last quarter.

Neutral/Negative Catalysts

  • Analysts have downgraded the stock due to challenges in the process chromatography business and uncertainties in the China diagnostics market. Financial performance in Q4 2025 showed declining net income (-200.59% YoY) and EPS (-204.22% YoY). No recent news or congress trading data to indicate positive sentiment.

Financial Performance

In Q4 2025, revenue increased by 3.85% YoY to $693.2M, but net income dropped significantly by -200.59% YoY to $720M. EPS also fell by -204.22% YoY to 26.65, and gross margin declined by -2.89% YoY to 49.74%. These metrics indicate weak financial performance and profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst ratings are negative. Citi downgraded the stock to Neutral from Buy with a reduced price target of $300 (down from $375), citing challenges in the company's growth engine. Wells Fargo and UBS also lowered price targets, highlighting weak guidance and margin concerns.

Wall Street analysts forecast BIO stock price to rise
1 Analyst Rating
Wall Street analysts forecast BIO stock price to rise
0 Buy
1 Hold
0 Sell
Hold
Current: 291.090
sliders
Low
340
Averages
340
High
340
Current: 291.090
sliders
Low
340
Averages
340
High
340
Citi
Patrick Donnelly
Buy
to
Neutral
downgrade
$300
AI Analysis
2026-04-07
Reason
Citi
Patrick Donnelly
Price Target
$300
AI Analysis
2026-04-07
downgrade
Buy
to
Neutral
Reason
Citi analyst Patrick Donnelly downgraded Bio-Rad to Neutral from Buy with a $300 price target.
Citi
Patrick Donnelly
Buy
to
Neutral
downgrade
$375 -> $300
2026-04-07
Reason
Citi
Patrick Donnelly
Price Target
$375 -> $300
2026-04-07
downgrade
Buy
to
Neutral
Reason
Citi analyst Patrick Donnelly downgraded Bio-Rad to Neutral from Buy with a price target of $300, down from $375. The firm does not see a recovery path for the company's process chromatography business, which it views as Bio-Rad's growth and margin growth engine. Further, the company faces uncertainties in the China diagnostics space, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BIO
Unlock Now

People Also Watch